企业 | 论坛 | 期刊 | 全站搜索
图库 | 疾病 | 报纸 | 大 杂 烩
论文 | 女人 | 词典 | Site Map
当前位置:Home > English > Health News > FDA Approves New Impetigo Treatment

FDA Approves New Impetigo Treatment

来源:WebMD Medical News 作者: Miranda Hitti 打印本文 放入收藏夹 收藏到新浪

摘要:April 13, 2007 -- The FDA today approved a new prescription antibacterialointment called Altabax to treat impetigo。 Impetigo is a highly contagious skin infection caused by bacteria。 Altabax represents the first new class of prescription topicalantibacterials to be approved by the FDA in ......


April 13, 2007 -- The FDA today approved a new prescription antibacterial ointment called Altabax to treat impetigo.

Impetigo is a highly contagious skin infection caused by bacteria. It's most common among children and is usually spread through physical contact with someone who has impetigo, or from sharing clothes, bedding, towels, or other objects.

Altabax is for patients who are at least 9 months old and have impetigo due to the common bacteria Staphylococcus aureus or Streptococcus pyogenes, states GlaxoSmithKline, which makes Altabax.

Altabax represents the first new class of prescription topical antibacterials to be approved by the FDA in nearly 20 years, notes GlaxoSmithKline.

Altabax is used twice daily for five days. Other prescription topical antibiotics are used as much as three times daily for up to 12 days, says GlaxoSmithKline.

Altabax Approval

The FDA approved Altabax based on effectiveness data from a study of 210 adults and children with impetigo.

A total of 139 patients received Altabax. The others patients got an ointment containing no medicine (placebo).

After five days of treatment, success was more common in the Altabax group than in the placebo group, according to GlaxoSmithKline.

The FDA says it also reviewed safety data on approximately 2,000 Altabax-treated adults and children who were at least 9 months old and another 1,000 patients who used other antibiotics or a placebo.

The most common Altabax-related adverse event was irritation at the application site. That problem affected less than 2% of the patients, notes the FDA.

发布日期:2007-5-15

分页:




网站地图 | RSS订阅 | 图文 | 版权说明 | 友情链接

亿腾慧联提供带宽
Copyright © 2008 39kf.com Inc. All rights reserved. 医源世界 版权所有 京ICP备05004837号
医源世界所刊载之内容一般仅用于教育目的。您从医源世界获取的信息不得直接用于诊断、治疗疾病或应对您的健康问题。如果您怀疑自己有健康问题,请直接咨询您的保健医生。医源世界、作者、编辑都将不负任何责任和义务。
本站内容来源于网络,转载仅为传播信息促进医药行业发展,如果我们的行为侵犯了您的权益,请及时与我们联系我们将在收到通知后妥善处理该部分内容
联系Email: